We have previously shown that the atrial natriuretic peptide (ANP) content of the anterior hypothalamic region of NaCIsensitive spontaneously hypertensive rats (SHR-S) is higher than that of Wistar-Kyoto (WKY) rats. ANP has been shown to inhibit neuronal norepinephrine release and to reduce the excitability of hypothalamic neurons. This study tested the hypothesis that blockade of endogenous ANP in the anterior hypothalamus by local microinjection of a monoclonal antibody to ANP (MAb KY-ANP-II) lowers blood pressure in SHR-S. Purified MAb KY-ANP-II (0.055 and 0.55 Mg) or control mouse IgG in 200 nl saline was microinjected into the anterior hypothalamic area (AHA) of conscious SHR-S and control WKY rats. As a further control, Mab KY-ANP-II (0.55 gg) was microinjected into the posterior hypothalamic area (PHA) of SHR-S. Anterior hypothalamic microinjection of MAb KY-ANP-II caused significant dose-related decreases in mean arterial pressure (MAP) and heart rate (HR) in SHR-S but not in WKY rats. Control injections of equal volumes of IgG had no effect on MAP or HR. Microinjection of Mab KY-ANP-II into PHA produced no significant alteration in MAP or HR in SHR-S. These data provide the first demonstration that endogenous ANP in a region of brain known to influence cardiovascular function mediates BP and HR control in the rat. These findings suggest that the increased endogenous ANP in the anterior hypothalamus of SHR-S may be involved in the central regulation of BP in this model. (J. Clin.
in the brain (1) (2) (3) (4) (5) (6) (7) . Immunoreactive ANP has been detected in various brain regions by radioimmunoassay ofextracted tissue and by immunocytochemistry (2, 4, (7) (8) (9) . ANP mRNA and ANP receptors have also been described, indicating that an intact ANP synthetic, processing, and effector system is present in rat brain (1) (2) (3) (4) (5) (6) 10) . Immunocytochemical data indicate that ANP-containing cell bodies are present in highest density in the anterior hypothalamic region adjacent to the anteroventral tip of the third ventricle (4, 9) . This region is involved in the development and maintenance of experimental hypertension and in fluid and electrolyte balance (4, 9) .
Previous studies from our laboratory have shown that the ANP content of the anterior hypothalamic region of the saltsensitive spontaneously hypertensive rat of the Okamoto strain (SHR-S) is significantly higher than that of the WistarKyoto (WKY) rat ( 11) . ANP content ofthe other brain regions examined, including posterior hypothalamic area (PHA), ventral hypothalamic area (VHA), pons, and medulla, did not differ between strains. The anterior hypothalamic region contains neurons that have a depressor effect when excited by electrical stimulation or noradrenergic input (12) (13) (14) (15) . ANP has been shown to inhibit norepinephrine (NE) release from peripheral nerve terminals (16) (17) (18) and from an adrenal pheochromocytoma (PC 12) cell line in culture (19) and to reduce the excitability of rat hypothalamic neurons in vivo (20) . We hypothesized that the increased ANP in the anterior hypothalamus of SHR-S may produce local tonic inhibition of NE release, thus reducing excitation of depressor neurons and elevating BP 8.3 . At the conclusion of the experiments, 1% methylene blue solution (200 nl) was administered into AHA or PHA through the cannula. The rat was then killed by decapitation without prior anesthesia and the cannula was removed from the brain. The brain was removed from the skull and sectioned at 30 Mm on a freezing microtome (Slee Medical Equipment Ltd., London, UK). Sections were mounted and stained with 1% thionin for verification of the microinjection site.
The monoclonal antibody used in these studies was the high affinity antibody against rat a-ANP, the 28-amino acid form of ANP, produced by Mukoyama, et al., and named MAb KY-ANP-II (23). MAb KY-ANP-II recognizes human (a-h ANP) and rat ANP (a-r ANP) equally and blocks the ability of both exogenous and endogenous ANP to elevate plasma cyclic GMP levels (24) . IgG containing MAb KY-ANP-II was purified from mouse ascites fluid (1 ml) using a protein A agarose column (25) . Retained IgG with MAb KY-ANP-II was eluted from the protein A column with 3 M MgCl2 and dialyzed against 0.9% saline overnight. Dialysate was then lyophilized and reconstituted to its original volume (I ml) with 0.9% saline. The purified IgG (1.1 mg/ml) with MAb KY-ANP-II bound 50% of I125-ANP (17,000 cpm) at 1:100,000 final dilution in a total volume of 500 M1 (26) . The 
Results
15 SHR-S and 10 WKY rats were studied. Histological examination confirmed that cannulae were properly placed in the anterior and central portions of AHA as defined by Saper et al. (27) in 8 SHR-S and 9 WKY rats and in PHA in 5 SHR-S rats. In 1 SHR-S, the cannula entered the sagittal sinus; in a second SHR-S, the cannula was in the third ventricle. In I WKY, cannula placement was in the dorsal hypothalamic area. These 3 rats were excluded from the analysis of experimental results.
SHR-S had significantly higher basal MAP and lower body weight (BW) than WKY rats at the time of study (Table I) . There was no difference in basal HR between SHR-S and WKY (Table I) . Microinjection of MAb KY-ANP-II into the AHA resulted in significant dose-related depressor and bradycardic responses in SHR-S (P < 0.01, two way ANOVA) but not in WKY rats (Fig. 1) . Both MAP and HR responses to MAb KY-ANP-II began almost immediately after injection, reached maximal levels at 5-10 min, and returned to baseline 30 min postinjection. MAP and HR responses to both doses of MAb KY-ANP-II were significantly greater in SHR-S than in WKY for the first 30 min postinjection (P < 0.05 for the lower dose; P < 0.01 for the higher dose, two way ANOVA) (Fig. 1) . Maximal high dose MAb KY-ANP-II-induced changes in MAP and HR in SHR-S were -17.5±1.1 mmHg and -42.5±5.1 bpm, respectively (Fig. 2) . Microinjection of IgG and saline vehicle into AHA did not alter MAP or HR significantly in either strain (Fig. 3) . Microinjection of MAb KY-ANP-II into the PHA did not cause significant alterations in MAP or HR in SHR-S (Fig. 4) .
Discussion
This study demonstrated that microinjection of MAb KY-ANP-II into AHA caused significant dose-related decreases in MAP and HR in SHR-S but not in WKY rats. Control injections ofequal volumes of IgG into AHA had no effect on MAP or HR. Further, injection of MAb KY-ANP-II into the PHA of SHR-S did not significantly alter MAP or HR. Taken together with the findings that anterior hypothalamic stores of endogenous ANP are increased selectively in SHR-S compared with WKY controls, and that ANP inhibits neuronal NE release, these data suggest that endogenous ANP in AHA may be involved in the centrally mediated regulation of BP in SHR. (30) . Our previous studies demonstrated that ANP stores are significantly elevated in the anterior hypothalamic region, but not in the posterior hypothalamic region, ventral hypothalamic region, pons, or medulla of 9-wk-old SHR-S compared with WKY (1 1 8) (7) (9) (8) Ab O.055ug Ab 0.55ug ANP into the intact rat, or application of ANP to brain slices in vitro, causes marked increases in cyclic GMP levels in hypothalamus and brain stem of SHR that are significantly greater than those in WKY controls (31, 34) . These observations suggest that ANP-sensitive particulate guanylate cyclase activity in the hypothalamus and brain stem is greater in SHR than in WKY rats (31, 34) . The functional significance of these alterations in endogenous brain ANP and its second messenger with respect to cardiovascular regulation has not been tested. A mechanism by which endogenous ANP in the AHA might participate in BP control is via regulation of NE release by AHA nerve terminals. Abundant evidence has shown that both endogenous and exogenous NE act in AHA to lower BP and HR via action on a2-adrenergic receptors. Chemical (6- pathway of normotensive Wistar rats selectively depletes NE stores in the anterior hypothalamus and increases BP and HR (15). Further, electrical stimulation of the anterior hypothalamus reduces BP and HR in both normotensive and hypertensive rats (14). Microinjection of NE or the a2-adrenergic agonists clonidine and guanabenz into AHA lowers BP and HR in the intact, conscious rat (13) . This effect is exaggerated in SHR-S, particularly after dietary NaCl supplementation, compared with normotensive controls. Receptor binding studies using [3Hjpara amino clonidine have shown that a2-adrenoreceptor numbers in anterior hypothalamus of SHR-S are significantly elevated compared with WKY (36). This observation, combined with the finding that the NE content of the anterior hypothalamic region is higher in SHR-S than in WKY (22) , presumably reflects upregulation of a2-adrenoreceptors in anterior hypothalamus of SHR-S in response to reduced local NE release. Reductions in endogenous NE activity in the AHA would be expected to decrease inhibition of sympathetic outflow and thereby cause BP to rise. ANP has been shown to reduce neuronal excitability in the rat hypothalamus (20) . When locally applied to individual neurons, ANP inhibits the neuronal firing rate (20). Further, ANP inhibits NE release from peripheral sympathetic nerve terminals (16) (17) (18) and from PC 12 cells in culture (19) . In this study, therefore, it would be expected that locally microinjected MAb KY-ANP-II would block the action of anterior hypothalamic ANP, reducing NE release and/or excitability of neurons in this brain area, thereby decreasing MAP and HR. This effect would be expected to be enhanced in SHR-S compared with WKY because of the higher levels of ANP found in anterior hypothalamus of the hypertensive strain. The observation that microinjection of MAb KY-ANP-II into AHA of WKY rats had no 
